文章：

工程细胞作为胶质母细胞瘤治疗方法

Engineered cells as glioblastoma therapeutics 

原文发布日期：2021-03-22 

英文摘要：

In spite of significant recent advances in our understanding of the genetics and cell biology of glioblastoma, to date, this has not led to improved treatments for this cancer. In addition to small molecule, antibody, and engineered virus approaches, engineered cells are also being explored as glioblastoma therapeutics. This includes CAR-T cells, CAR-NK cells, as well as engineered neural stem cells and mesenchymal stem cells. Here we review the state of this field, starting with clinical trial studies. These have established the feasibility and safety of engineered cell therapies for glioblastoma and show some evidence for activity. Next, we review the preclinical literature and compare the strengths and weaknesses of various starting cell types for engineered cell therapies. Finally, we discuss future directions for this nascent but promising modality for glioblastoma therapy. 

摘要翻译：

尽管近期我们在胶质母细胞瘤的遗传学和细胞生物学理解上取得了重大进展，但迄今为止，这些进展尚未转化为针对该癌症的改进治疗方法。除小分子、抗体和工程化病毒方法外，工程化细胞也正被探索作为胶质母细胞瘤的治疗手段，包括CAR-T细胞、CAR-NK细胞，以及经过改造的神经干细胞和间充质干细胞。本文将从临床试验研究入手，综述该领域现状。这些研究已证实工程化细胞治疗胶质母细胞瘤的可行性和安全性，并显示出一定的活性证据。接着，我们回顾临床前文献，比较不同起始细胞类型在工程化细胞治疗中的优势与局限。最后，我们将探讨这一处于起步阶段但前景广阔的胶质母细胞瘤治疗模式的未来发展方向。

原文链接：

Engineered cells as glioblastoma therapeutics